KOICHI TAKAHASHI to Isocitrate Dehydrogenase
This is a "connection" page, showing publications KOICHI TAKAHASHI has written about Isocitrate Dehydrogenase.
Connection Strength
1.957
-
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nat Commun. 2021 05 10; 12(1):2607.
Score: 0.544
-
Precision medicine in AML: overcoming resistance. Int J Hematol. 2024 Oct; 120(4):439-454.
Score: 0.170
-
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv. 2023 06 13; 7(11):2378-2387.
Score: 0.157
-
Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol. 2022 11; 97(11):1443-1452.
Score: 0.149
-
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J. 2022 01 25; 12(1):10.
Score: 0.143
-
Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. J Exp Med. 2021 05 03; 218(5).
Score: 0.136
-
Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia. Am J Hematol. 2021 05 01; 96(5):E154-E157.
Score: 0.134
-
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer. 2021 02 01; 127(3):381-390.
Score: 0.131
-
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015 Aug; 90(8):732-6.
Score: 0.091
-
IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia. 2016 Apr; 30(4):980-4.
Score: 0.091
-
Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission. Am J Hematol. 2015 Jul; 90(7):E134-5.
Score: 0.091
-
Phospholipid metabolic adaptation promotes survival of IDH2 mutant acute myeloid leukemia cells. Cancer Sci. 2024 Jan; 115(1):197-210.
Score: 0.040
-
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood Cancer J. 2023 09 21; 13(1):148.
Score: 0.040
-
A Phase Ib/II Study of Ivosidenib with Venetoclax ? Azacitidine in IDH1-Mutated Myeloid Malignancies. Blood Cancer Discov. 2023 07 05; 4(4):276-293.
Score: 0.039